News about "Viatris "

Viatris Wins US FDA Approval for Once-Weekly Gwyn Lo Contraceptive Patch

Viatris has received US Food and Drug Administration (FDA) approval for Gwyn Lo, a once-weekly low-dose estrogen contraceptive patch, expanding women's health treatment options.

Viatris | 30/07/2026 | By News Bureau

Viatris Reports Positive Phase 3 Results for VR-205 in IgA Nephropathy in Japan

Viatris reported positive Phase 3 results for VR-205 in Japanese adults with primary IgA nephropathy and plans to submit a New Drug Application (NDA) in Japan by the end of 2026.

Viatris | 01/07/2026 | By News Bureau |  259

Viatris Appoints Paul Campbell as Interim Chief Financial Officer

Viatris announces Chief Financial Officer (CFO) transition as Theodora “Doretta” Mistras departs and Paul Campbell is named interim CFO, ensuring leadership continuity.

Viatris | 05/05/2026 | By News Bureau |  166

Viatris Secures Japan Approval for Effexor SR as First Treatment for Generalised Anxiety Disorder

Japan’s health ministry approves Effexor SR for adult GAD, marking the first and only authorised treatment in the country and expanding access to mental health care.

Viatris | 24/03/2026 | By News Bureau |  180

Viatris Inc sNDA for MR-141 Accepted by U.S. Food and Drug Administration for Presbyopia Treatment

The US FDA has accepted Viatris’ supplemental application for phentolamine ophthalmic solution 0.75 percent to treat presbyopia and advancing to a potential non-invasive therapy.

Viatris | 02/03/2026 | By News Bureau |  197

Biocon Raises INR 4,150 Crore via QIP

Biocon has successfully raised INR 4,150 crore through a Qualified Institutions Placement (QIP), with the proceeds set to be primarily used to fund the cash consideration payable to Mylan Inc. (Viatris) for the buyout of its stake in Biocon Biologics, including the repayment of related acquisition debt.

Viatris | 15/01/2026 | By News Bureau |  162

Biocon Biologics Secures Global Rights to Hulio

The new agreement supersedes the existing collaboration agreement between Biocon Biologics and Fujifilm Kyowa Kirin Biologics (FKB) for biosimilar Adalimumab, under which Biocon Biologics only had commercialisation rights.

Viatris | 23/12/2025 | By News Bureau |  273

Viatris to Receive USD 400 Million in Cash and USD 415 Million in Equity Shares of Biocon

Viatris is set to receive USD 400 million in cash and USD 415 million in Biocon equity shares as part of a revised agreement, accelerating the end of non-compete restrictions in the biosimilars space and enabling both companies to pursue expanded market opportunities.

Viatris | 08/12/2025 | By Dineshwori |  149

Viatris Acquires Aculys Pharma, Secures Exclusive Rights to Pitolisant and Spydia in Japan

Viatris has completed the acquisition of Aculys Pharma, a clinical stage biopharmaceutical company focused on commercialising innovative treatments for neurological conditions.

Viatris | 16/10/2025 | By Dineshwori |  877

Viatris Names Andrew Enrietti Chief Administrative and Transformation Officer

Viatris Inc. has appointed Andrew Enrietti as its Chief Administrative and Transformation Officer – a newly created position.

Viatris | 20/08/2025 | By Dineshwori |  346